Vanguard Group's 13G/A Filing for RAPT Therapeutics

The Vanguard Group, Inc. filed an amendment to its Schedule 13G for RAPT Therapeutics Inc, reporting ownership of 696,188 shares, representing 4.2% of the company's common stock. The filing indicates that Vanguard has shared voting power over 60,162 shares and shared dispositive power over 65,356 shares. The securities are held by Vanguard's clients, including investment companies and managed accounts, with no single client owning more than 5% of the shares. The filing certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.